Introduction
============

Depression and serotonin
------------------------

Major depression is the most prevalent form of mental illness, twice as frequent in women as in men (Doris et al., [@B23]; Fava and Kendler, [@B28]), and is predicted to increase from fourth to second (first in high income countries) highest global burden of disease by 2030 (Ustun et al., [@B112]; Mathers and Loncar, [@B65]). There is a need for improved antidepressant treatments since only 30% of patients remit with current strategies (Trivedi et al., [@B109],[@B110], [@B111]), while 15% attempt suicide (Mann et al., [@B63]; Mann, [@B62]). Although other neurotransmitters (e.g., noradrenaline, dopamine, glutamate, neurotrophins) are indirectly involved in depression (Blier, [@B14]; Duman, [@B25]; Nestler and Carlezon Jr., [@B73]; Skolnick et al., [@B99]), multiple lines of evidence implicate reduced 5-HT neurotransmission as a primary defect in depression (Millan, [@B67]; Wong et al., [@B118]; Tremblay and Blier, [@B108]; Jans et al., [@B46]; aan het Rot et al., [@B1]). Virtually all antidepressant treatments, including serotonin reuptake inhibitors (SSRIs), increase 5-HT neurotransmission, either directly or indirectly (Blier, [@B14]; Berton and Nestler, [@B11]; Savitz et al., [@B93]).

5-HT1A receptors and the 5-HT system
------------------------------------

The brain serotonin (5-HT) system originates from neurons of the raphe nuclei that express tryptophan hydroxylase 2 (TPH2), the rate-limiting enzyme for 5-HT synthesis (Walther et al., [@B115]). These neurons project widely throughout the brain (Hornung, [@B42]) to regulate many physiological functions, including sleep, mood and stress reactivity and are implicated in mental illnesses, including MDD and anxiety (Barnes and Sharp, [@B9]; Young and Leyton, [@B120]; Gordon and Hen, [@B29]; Lanfumey et al., [@B51]; Savitz et al., [@B93]). Among the 17 human 5-HT receptor genes, we have focused on the 5-HT1A receptor since it is abundant in corticolimbic regions that are implicated in mood and emotion (Albert et al., [@B4]; Albert and Lemonde, [@B5]). The 5-HT1A receptor also functions presynaptically as the major somatodendritic autoreceptor on 5-HT neurons (Sotelo et al., [@B100]; Riad et al., [@B85]) where it acts as a "brake" to inhibit the activity of the entire 5-HT system (Hjorth et al., [@B41]; Richer et al., [@B89]; Bortolozzi et al., [@B19]) (Figure [1](#F1){ref-type="fig"}). Hence, the mechanisms that regulate 5-HT1A autoreceptor levels set the tone of the 5-HT system.

![**Regulation of 5-HT1A receptors in depression**. Shown figuratively are 5-HT1A-expressing presynaptic raphe neuron and post-synaptic prefrontal cortical neuron. The 5-HT1A gene and its regulators (Deaf1, Freud-1, Freud-2, REST, Hes) are shown; 5-HT1A receptors (circle/triangle) and serotonin (triangles) are shown to indicate expected changes in their levels in depression. In depression, 5-HT1A receptor RNA and protein levels are increased presynaptically, leading to inhibition of 5-HT neurons (red-) and reduced firing. Paradoxically, the presynaptic levels of repressors REST and Deaf1 are increased, and there is also a trend for increase in Freud-1, perhaps to compensate for 5-HT1A overexpression due to the G(−1019) allele, for example. Post-synaptically, 5-HT1A receptors appear reduced, and levels of Deaf1 are also lower, although Freud-1 and Freud-2 (trend) increase. See text for details and references.](fnins-04-00035-g001){#F1}

5-HT1A Receptors in Depression
==============================

5-HT1A receptors in animal models of depression
-----------------------------------------------

Despite their limited validity to model human depression, animal behavioral studies have provided valuable insights into the biological function of 5-HT1A receptors in depression and anxiety. Importantly, 5-HT1A-null mice display increased anxiety behavior (Heisler et al., [@B38]; Parks et al., [@B78]; Ramboz et al., [@B84]) and are unresponsive to SSRI treatment (Santarelli et al., [@B91]), while early developmental overexpression of the 5-HT1A receptor decreases anxiety (Kusserow et al., [@B50]). 5-HT1A receptor expression in early postnatal forebrain of 5-HT1A−/− mice rescues the anxiety phenotype, suggesting that post-synaptic 5-HT1A receptors are critical in the development of the anxiety phenotype (Gross et al., [@B33]). Conversely, mice with a 30% increase in 5-HT1A autoreceptors display reduced 5-HT neuron firing, reduced 5-HT release, increased depression behavior, but no change in anxiety behavior (Richardson-Jones et al., [@B88]). Hence, while reduction in post-synaptic 5-HT1A receptors is implicated in anxiety, increased levels of presynaptic 5-HT1A autoreceptors inhibit 5-HT neurotransmission and leads to depression (Figure [1](#F1){ref-type="fig"}).

5-HT1A receptors in clinical depression
---------------------------------------

In human depression, there remain conflicting findings concerning changes in 5-HT1A binding potential (Savitz et al., [@B93]). Most studies find reductions in post-synaptic 5-HT1A receptors in subsets of prefrontal and temporal cortical regions in depression (Sargent et al., [@B92]; Bhagwagar et al., [@B13]; Shively et al., [@B96]; Moses-Kolko et al., [@B70]) and anxiety (Tauscher et al., [@B107]; Neumeister et al., [@B74]; Sullivan et al., [@B104]; Lanzenberger et al., [@B52]; Nash et al., [@B71]; Akimova et al., [@B3]). In contrast, 5-HT1A autoreceptors are increased in depressed patients (Parsey et al., [@B80],[@B81]) and in post-mortem raphe tissue from depressed suicide victims (Stockmeier et al., [@B101]; Boldrini et al., [@B18]). However, decreases in raphe 5-HT1A binding have also been reported, but may reflect a reduction in 5-HT neurons (Drevets et al., [@B24]). These region-specific alterations in 5-HT1A receptor levels in depression are consistent with a global reduction in 5-HT neurotransmission, since increased 5-HT1A autoreceptors reduce 5-HT neuronal activity, while reduced post-synaptic 5-HT1A receptors reduce behavioral response to 5-HT (Albert and Lemonde, [@B5]).

5-HT1A receptors in antidepressant response
-------------------------------------------

Although SSRIs rapidly enter the brain and block 5-HT reuptake, chronic 3-week treatment is required for clinical response, due to recurrent inhibition of raphe activity by 5-HT1A autoreceptors (Figure [1](#F1){ref-type="fig"}). During this period, 5-HT1A autoreceptors desensitize (Le Poul et al., [@B58]; Mochizuki et al., [@B68]; Shen et al., [@B95]; Elena Castro et al., [@B26]), leading to reduced 5-HT1A RNA and autoreceptor levels, particularly in animal models of depression and depressed subjects (Welner et al., [@B117]; Fanelli and McMonagle-Strucko, [@B27]; Sibug et al., [@B97]; Le Poul et al., [@B57]; Meltzer et al., [@B66]; Rabiner et al., [@B83]; Berney et al., [@B10]), resulting in restoration of raphe firing activity and 5-HT release. Chronic antidepressant treatment reverses changes in 5-HT1A receptor RNA expression in chronic stress models (Burnet et al., [@B21]; Greenwood et al., [@B32], [@B31]; Morley-Fletcher et al., [@B69]), as well as in depression (Lopez et al., [@B60]; Lopez-Figueroa et al., [@B61]). However, several studies in "normal" animals have found that chronic antidepressant treatments desensitize 5-HT1A receptors without a concomitant reduction in receptor levels (Le Poul et al., [@B58]; Elena Castro et al., [@B26]; Rossi et al., [@B90]). Because acute desensitization (uncoupling and internalization) occurs rapidly (second--minute) and is reversible (Riad et al., [@B86], [@B87]), we postulated that acute desensitization is not sufficient for antidepressant response, but that a reduction in the synthesis of new 5-HT1A receptors may be required, and could account for the longer time course of the treatment (Albert et al., [@B4]; Albert and Lemonde, [@B5]). Interestingly, a 30% reduction in 5-HT1A autoreceptors is sufficient to permit a rapid and robust response to chronic SSRI treatment in mice that do not otherwise respond (Richardson-Jones et al., [@B88]), suggesting that transcriptional down-regulation of the 5-HT1A mRNA could be a key mechanism in determining antidepressant response.

Transcriptional Regulation of the 5-HT1A Receptor Gene in Mental Illness
========================================================================

Transcriptional regulation of the 5-HT1A receptor gene
------------------------------------------------------

Based on the hypothesis that impaired repression of the 5-HT1A receptor gene may predispose individuals to depression, we have identified key transcription regulators of the 5-HT1A receptor (Albert et al., [@B4]; Albert and Lemonde, [@B5]). The 5-HT1A receptor gene is intronless with a non-selective CG-rich housekeeping promoter containing multiple strong Sp1/MAZ enhancers that drive expression in all cells (Albert et al., [@B4]; Parks and Shenk, [@B79]; Storring et al., [@B102]) and an upstream repressor region that silences its expression in non-neuronal cells, but also represses transcription in neuronal cells that express 5-HT1A receptors (Ou et al., [@B76]; Lemonde et al., [@B55]). The promoter also contains an NFkB-response element, that may mediate 5-HT1A induction in immune cells, although its function in neurons remains unaddressed. Repressors include Freud-1/CC2D1A and Freud-2/CC2D1B (Five-prime Repressor Element Under Dual repression binding protein), calcium-sensitive repressors of pre- (Freud-1) and post-synaptic 5-HT1A receptor expression in neurons (Ou et al., [@B77]; Lemonde et al., [@B55]; Hadjighassem et al., [@B35]). We have also identified Deaf1 and Hes1/Hes5 as regulators at the C(−1019)G 5-HT1A polymorphism that repress 5-HT1A autoreceptor transcription at the C-allele but not the G-allele (Lemonde et al., [@B56]). Consistent with this, the G/G genotype is associated increased 5-HT1A autoreceptor binding potential in depressed subjects (Parsey et al., [@B81]). Deaf1 is colocalized with 5-HT1A receptors in raphe and post-synaptic neurons, and expressed from development to adulthood; while Hes proteins are restricted to neural precursors and immature neurons. In Hes1−/− mice, 5-HT1A receptor RNA expression is greatly up-regulated in embryonic midbrain (Jacobsen et al., [@B45]), suggesting that the G(−1019) allele may result in an early embryonic alteration in 5-HT1A receptor levels. Interestingly, Deaf1 displays tissue-specific activity, *repressing* 5-HT1A autoreceptor RNA and protein expression in raphe cells, but *enhancing* 5-HT1A promoter activity in non-serotonergic neurons (Lemonde et al., [@B56]; Czesak et al., [@B22]). Based on this, the G-allele is expected to increase 5-HT1A autoreceptor levels to reduce 5-HT neuronal activity, and decrease post-synaptic 5-HT1A receptors, synergistically reducing 5-HT neurotransmission.

Transcriptional dysregulation of the 5-HT1A receptor gene in mental illness
---------------------------------------------------------------------------

Changes in 5-HT1A receptor RNA and protein levels are observed in brain regions of MDD subjects as discussed above, and suggest that alterations in 5-HT1A receptor gene expression could confer susceptibility. We initially associated the C(−1019)G polymorphism with MDD and suicide (Lemonde et al., [@B56]). This association has been replicated in most studies (Parsey et al., [@B81]; Anttila et al., [@B7]; Kraus et al., [@B49]; Le François et al., [@B53]; Kishi et al., [@B48]; Neff et al., [@B72]). In our original study (Lemonde et al., [@B56]), both G/G genotype (*P* = 0.0134\*) and G-allele frequencies (*P* = 0.0043\*\*) were associated with depression in females (81 normal; 74 depressed). Males (53 control; 55 depressed) showed the same trends for genotype and allele frequency (*P* = 0.0846 and 0.0574), but they were not significant, suggesting a stronger association in females. However the allele and genotype ratios in depressed/control were similar (G/G genotype frequency 2.36× and 2.39× for females and males; G-allele frequency 1.45× and 1.33×). Hence there does not appear to be a clear gender effect of the polymorphism for association with depression.

Recently, the homozygous 5-HT1A G/G(−1019) risk genotype has been associated with increased levels of 5-HT1A autoreceptors in the raphe of depressed and bipolar depressed subjects (Parsey et al., [@B81]; Sullivan et al., [@B103]), which is consistent with the increase in 5-HT1A autoreceptors observed in post-mortem studies of depressed suicides (Stockmeier et al., [@B101]; Drevets et al., [@B24]; Boldrini et al., [@B18]). This association supports the hypothesis that the 5-HT1A G(−1019) allele is a risk factor for depression by increasing 5-HT1A autoreceptor levels to reduce 5-HT neurotransmission (Albert and Lemonde, [@B5]). Interestingly, in serotonin neurons of depressed females, RNA levels of both Deaf1 and REST \[a repressor of 5-HT1A receptor transcription (Lemonde et al., [@B55])\] are increased, suggesting a compensatory change to re-establish normal 5-HT1A autoreceptor levels (Goswami et al., [@B30]). Despite these compensatory changes, there was a trend toward increased 5-HT1A RNA levels in depressed female raphe tissue, consistent with previous studies showing increased 5-HT1A autoreceptors. The recent finding that mice with selective increase in presynaptic 5-HT1A autoreceptors have depression-like behavior and are resistant to antidepressants (Richardson-Jones et al., [@B88]), provides validation of the hypothesis that dysregulation of the 5-HT1A autoreceptor is implicated in major depression (Albert et al., [@B4]; Albert and Lemonde, [@B5]).

In addition to its association with depression, we and others have found that the G(−1019) allele associates with reduced response to chronic SSRI or SSRI/pindolol treatment (Lemonde et al., [@B54]; Le François et al., [@B53]; Villafuerte et al., [@B114]; Yevtushenko et al., [@B119]). Interestingly, antidepressant response to flibanserin, a 5-HT1A agonist which directly targets 5-HT1A receptor desensitization, was the most attenuated in subjects with the G/G genotype. This suggests that the Deaf1 site is critical for antidepressant action to down-regulate 5-HT1A autoreceptor expression. However, particularly in Asian populations where the G-allele is more prevalent, there is evidence that SSRI response is greater in the G/G genotype (Kato et al., [@B47]), suggesting that alternate regulatory factors (e.g., Freud-1, REST) could augment 5-HT1A autoreceptor down-regulation. Therefore, mechanisms preventing 5-HT1A autoreceptor de-repression could provide effective therapy for treatment-resistant depressed patients.

Thus, alterations in transcription factors that regulate 5-HT1A expression could either contribute to the dysregulation of the receptor or compensate for changes associated with mental illness.

Targeting 5-HT1A Autoreceptors for Antidepressant Response
==========================================================

Targeting 5-HT1A autoreceptors to augment to antidepressant efficacy
--------------------------------------------------------------------

Several compounds that target 5-HT1A receptors including pindolol and buspirone, have been used in augmentation with SSRIs to accelerate or enhance their antidepressant action. Pindolol is a β-adrenergic receptor blocker also shown to act as a weak partial agonist of the 5-HT1A receptor (Newman-Tancredi et al., [@B75]). Pindolol preferentially competes with endogenous 5-HT at presynaptic 5-HT1A receptors (Rabiner et al., [@B83]; Serrats et al., [@B94]) to increase serotonergic neurotransmission. Clinical studies have demonstrated that pindolol can accelerate response to SSRIs, even in drug-resistant depression (Artigas et al., [@B8]; Blier and Bergeron, [@B15]; Portella et al., [@B82]). However, the ability of pindolol to improve SSRI treatment has not been consistent, in part due to low occupancy of 5-HT1A receptor sites at the dose of pindolol used in most studies (Martinez et al., [@B64]). In contrast to pindolol, buspirone functions as strong 5-HT1A partial agonist that can specifically desensitize 5-HT1A autoreceptors (Sim-Selley et al., [@B98]) to relieve serotonergic autoinhibition. Similarly to pindolol, buspirone was able to improve SSRI treatment in some studies (Harvey and Balon, [@B37]; Trivedi et al., [@B109]) but not consistently (Blier and Ward, [@B17]). Differences between pindolol and buspirone appear due to their differential antagonist or agonist activity at 5-HT1A receptors. For example, unlike buspirone, acute pindolol treatment potentiates citalopram-mediated increase in 5-HT in rats (Hjorth, [@B40]). However, buspirone has unique agonist activities that can differ from full agonists like 5-HT. Buspirone and its analog BMY7378 inhibited Gi2-dependent constitutive activity of the 5-HT1A receptor, while full agonists (5-HT, 8OH-DPAT) or antagonists WAY100635, pindolol and NAN-190 had little or no effect (Albert et al., [@B6]). In the raphe nuclei, buspirone recruits Gi2, Gi3, and Go to the 5-HT1A receptor and inhibits adenylyl cyclase, while 8OH-DPAT only recruited Gi3 and did not inhibit forskolin-stimulated adenylyl cyclase (Valdizan et al., [@B113]). The preferential activity of buspirone in raphe cells may explain the efficacy of buspirone to decrease 5-HT synthesis in olfactory-bulbectomized rats (Watanabe et al., [@B116]). Other compounds that act at 5-HT1A receptors, such as atypical antipsychotics aripiprazole (Abilify) or SNRI milnacipran (Savella), can also ameliorate response to SSRIs. However, while these compounds desensitize the 5-HT1A autoreceptor (Mochizuki et al., [@B68]), they have other targets that can participate in their antidepressant actions. In addition it is important to note that drugs that indirectly target 5-HT neurons (Guiard et al., [@B34]) such as bupropion or α2-adrenergic receptor antagonists may also enhance response to SSRI response (Tremblay and Blier, [@B108]; Trivedi et al., [@B109]; Blier et al., [@B16]). Thus, the concept of a multi-system therapeutic strategy appears to provide enhanced treatment response and remission rates compared to SSRI alone (Blier et al., [@B16]).

Targeting 5-HT1A gene transcription for the treatment of depression
-------------------------------------------------------------------

The inconsistent results using 5-HT1A agonists to augment or accelerate response to SSRIs, may be due to their limited ability to decrease presynaptic 5-HT1A receptor levels. In fact, effective treatment appears to require long-term adaptive changes in addition to rapid desensitization of 5-HT1A autoreceptors, such as reduced transcription of 5-HT1A autoreceptors or induction of post-synaptic 5-HT1A receptors. For example, it was recently shown that aripiprazole increases hippocampal and cortical 5-HT1A receptors (Han et al., [@B36]). This suggests that long-term activation of presynaptic 5-HT1A receptors might trigger transcriptional changes that follow the rapid initial desensitization of the receptors and lead to long-term alterations in 5-HT1A receptor levels. The recent finding that a 30% transcription-mediated increase in 5-HT1A autoreceptors is sufficient to abolish response to chronic antidepressant treatment in adult mice (Richardson-Jones et al., [@B88]), suggests that an ability to even slightly down-regulate 5-HT1A autoreceptor expression could greatly improve SSRI response in treatment-resistant patients.

Additionally, it would be important to determine how 5-HT1A agonists affect the expression and activity of key transcriptional regulators of the 5-HT1A receptor gene. Recent findings suggested that alterations in Deaf1 occur both in raphe and prefrontal cortex of depressed females (Szewczyk et al., [@B105]; Goswami et al., [@B30]), suggesting that females may be more responsive to drugs that could upregulate Deaf1 expression. Up-regulation of Deaf-1 levels would be expected to repress presynaptic and induce post-synaptic 5-HT1A gene expression to increase serotonin neurotransmission in heterozygous or C/C homozygous subjects. However, patients with the 5-HT1A G/G(−1019) genotype would be expected to be resistant since the G-allele does not respond to Deaf1.

Since depression is twice as frequent in females compared to males, gender-specific alterations in 5-HT1A autoreceptor expression could mediate an increased susceptibility. In female rats and serotonin transporter-deficient female mice, ovariectomy results in increased raphe 5-HT1A receptor RNA and binding (Bouali et al., [@B20]; Le Saux and Di Paolo, [@B59]) and increased anxiety behavior (Imwalle et al., [@B43]), while estrogen treatment reverses changes in 5-HT1A levels and anxiety, increasing raphe responsiveness (Abizaid et al., [@B2]). Similarly, estrogen receptor-beta knockout female mice display increased anxiety and reduced raphe 5-HT levels (Imwalle et al., [@B43]). In female rhesus macaques, ovariectomy leads to an increase in nuclear NFkB in 5-HT raphe neurons, while estrogen/progesterone reverses this (Bethea et al., [@B12]) and reduces 5-HT1A autoreceptor protein level (Henderson and Bethea, [@B39]), which could be driven by NFkB-response element in the 5-HT1A promoter. Thus estrogen appear to be protective for anxiety and negatively regulates 5-HT1A autoreceptor levels to enhance raphe activity, but the mechanisms of this regulation remain to be clarified.

Antidepressant treatments could also target cortical 5-HT1A receptors, which are reduced in depression. Down-regulation of Freud-1 or Freud-2 in post-synaptic regions could lead to an increase in 5-HT1A receptor RNA and normalize post-synaptic 5-HT1A receptor expression and restore response of post-synaptic neuron to 5-HT. Interestingly, Freud-1 RNA and protein was down-regulated in the prefrontal cortex of chronically stressed rats (Iyo et al., [@B44]), while 5-HT1A RNA level was increased, although 5-HT1A protein was reduced. Similarly in the prefrontal cortex of younger (\<58 years) depressed subjects (especially males), Freud-1 RNA and protein were decreased, while 5-HT1A receptor protein was also reduced (Szewczyk et al., [@B106]). Thus, despite increased 5-HT1A RNA other post-translational processes, such as receptor down-regulation, may reduce cortical 5-HT1A protein levels in depression. Interestingly, cortical Freud-1 levels were not altered by chronic treatment of macaques with SSRI, suggesting that other types of antidepressant treatments may be required to induce this effect. Alternately, Freud-1 activity could be reduced, for example by calcium mobilization, which inactivates Freud-1 (Ou et al., [@B77]).

Conclusion
==========

Alterations in pre- and post-synaptic 5-HT1A receptor RNA and protein expression in depression suggest that transcriptional dysregulation of the receptor is involved. Currently used 5-HT1A selective ligands are well known to induce desensitization of 5-HT1A receptors, but should be tested for their ability to alter 5-HT1A gene transcription. Among the known transcriptional regulators of the 5-HT1A receptor, Deaf-1 is a very attractive target due to its ability to repress presynaptic 5-HT1A expression, while inducing post-synaptic 5-HT1A receptors. Thus, identification of ligands or strategies that activate or induce Deaf-1 could simultaneously target pre- and post-synaptic 5-HT1A receptor expression to increase serotonergic tone.
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